Humana (NYSE:HUM) had its price objective raised by Barclays from $327.00 to $358.00 in a report released on Friday morning, AnalystRatings.com reports. They currently have an overweight rating on the insurance provider’s stock.
Several other equities analysts have also recently issued reports on HUM. Argus boosted their target price on shares of Humana to $370.00 and gave the company a buy rating in a research note on Wednesday, November 20th. Cantor Fitzgerald upgraded Humana from a neutral rating to an overweight rating and raised their target price for the company from $300.00 to $345.00 in a research report on Monday, August 12th. ValuEngine lowered Humana from a buy rating to a hold rating in a research note on Wednesday, December 4th. Mizuho assumed coverage on Humana in a research report on Thursday, October 17th. They set a buy rating and a $316.00 target price on the stock. Finally, BMO Capital Markets cut shares of Humana from an outperform rating to a market perform rating and reduced their price objective for the stock from $345.00 to $290.00 in a research report on Monday, September 30th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of $326.65.
Shares of HUM stock opened at $348.14 on Friday. The stock has a 50 day moving average of $316.55 and a 200 day moving average of $282.83. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.46. The stock has a market cap of $46.10 billion, a P/E ratio of 23.93, a P/E/G ratio of 1.49 and a beta of 0.90. Humana has a twelve month low of $225.65 and a twelve month high of $350.46.
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date is Monday, December 30th. Humana’s payout ratio is 15.12%.
In other news, insider Timothy Alan Wheatley sold 15,019 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $345.21, for a total transaction of $5,184,708.99. Also, Director James J. /Ky Obrien sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $345.21, for a total value of $863,025.00. 0.54% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of HUM. Endurance Wealth Management Inc. grew its holdings in Humana by 354.5% in the 3rd quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock valued at $26,000 after buying an additional 78 shares in the last quarter. Next Capital Management LLC purchased a new stake in shares of Humana during the 2nd quarter valued at approximately $27,000. Quest Capital Management Inc. ADV purchased a new stake in Humana in the 3rd quarter valued at about $30,000. Penserra Capital Management LLC acquired a new position in Humana in the third quarter valued at about $31,000. Finally, Advantage Investment Management LLC boosted its stake in Humana by 287.1% during the second quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock worth $32,000 after buying an additional 89 shares during the period. 94.61% of the stock is owned by hedge funds and other institutional investors.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Story: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.